<DOC>
	<DOCNO>NCT01084486</DOCNO>
	<brief_summary>Abstract Background : Insulin resistance important role development nonalcoholic fatty liver disease ( NAFLD ) involve pathological process : hepatic steatosis atherosclerosis . Therefore , treatment NAFLD insulin sensitizer likely favorable effect towards hepatic steatosis cardiovascular outcome . Objectives : The present study investigate effect metformin arterial property , metabolic parameter liver function patient NAFLD . Methods In randomized , placebo control study , 63 patient NAFLD assign one two group : Group 1 receive daily metformin ; Group 2 receive placebo . Pulse wave velocity ( PWV ) augmentation index ( AI ) perform use SphygmoCor ( version 7.1 , AtCor Medical , Sydney , Australia ) baseline end 4-month treatment period.. Metabolic measure serum adiponectin level determine .</brief_summary>
	<brief_title>Effect Treatment With Insulin Sensitizer Arterial Properties , Metabolic Parameters Liver Function Patients With Nonalcoholic Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>In singlecenter study , 63 patient ( 32 male 31 female ) diagnose nonalcoholic fatty liver disease recruit outpatient clinic evaluate study . Patients history unstable angina , MI , CVA major surgery within six month precede entrance study . Patients unbalanced endocrine disease disease might affect absorption medication . Patients plasma creatinine &gt; 1.5 mg/dl , electrolyte abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>nonalcoholic fatty liver disease</keyword>
	<keyword>Pulse wave velocity</keyword>
	<keyword>augmentation index</keyword>
	<keyword>metformin</keyword>
</DOC>